Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients

What Was Tested

Researchers studied Terlipressin in this randomized controlled trial publication.

However, its effects on variceal pressure have been poorly investigated.

This study investigated the variceal, splanchnic and systemic hemodynamic effects of terlipressin.

Who Took Part

According to the abstract, 14 patients were involved.

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

The same measurements were repeated 60 min later.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Terlipressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Terlipressin study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Terlipressin, giving a reference point.

Hepatic venous pressure gradient, variceal pressure and systemic hemodynamic parameters were obtained.

What Was Measured

Topics PubMed links to this paper include Antihypertensive Agents, Blood Pressure, Esophageal and Gastric Varices, Hemodynamics, Liver Cirrhosis, Lypressin and Portal System.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Terlipressin in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Journal of hepatology), a journal based in Netherlands.

More context: the Terlipressin compound page, all human trials.